CD19 and cancer: In large B cell lymphoma patients [73], anti-CD19 CAR T cells effectively eliminate most of the CD19+ cancer cells; however, CD19− cancer cells escape the targeted therapy, and can then proliferate at will and perpetuate the cancer [74].